1100 13th Street, NW, Suite 750Washington, DC 20005202.887.6400Customer Service: 800.544.0155
All Contents © 2019The Kiplinger Washington Editors
These biotechnology companies are making important strides in treating many forms of cancer.
Investors looking for a high income stream often balk at closed-end funds (CEFs) because of their higher fees.
CEFs’ average annual fees sit at 1.09% (or $109 for every $10,000 invested),...
Check out our weekly earnings calendar and read the latest quarterly earnings previews.
More Investing News »